Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
BAY-850 is an inhibitor of the ATPase family AAA domain-containing protein 2 (ATAD2; IC50 = 22 nM in a time-resolved FRET assay using a tetra-acetylated histone H4 peptide).1 It is selective for ATAD2 over a panel of 32 bromodomain family proteins, including ATAD2B, a panel of 354 kinases, and a panel of 25 G protein-coupled receptors (GPCRs) at 1 µM. BAY-850 induces dimerization of ATAD2 in a concentration-dependent manner in a cell-free assay and inhibits the ATAD2-chromatin interaction in MCF-7 breast cancer cells in a fluorescence recovery after photobleaching (FRAP) assay. It induces apoptosis and cell cycle arrest in, and inhibits proliferation, invasion, and migration of, PA-1 and SKOV3 ovarian cancer cells when used at a concentration of 5 µM.2 BAY-850 (20 mg/kg) reduces tumor volume and the percentage of lung metastases in a SKOV3 mouse xenograft model. See the Structural Genomics Consortium (SGC) website for more information.
WARNING This product is not for human or veterinary use.
1. Isoform-
2. ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE. Cell Death Dis. 14(7), 456 (2023).